Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 20/20 | 1.00 |
| ▸ | HCRTR2 | O43614 | 20/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL439572 | 0.93 | HCRTR2 (0.87) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL439578 | 0.91 | HCRTR1 (0.83) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL441336 | 0.91 | HCRTR2 (0.83) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL439577 | 0.88 | HCRTR1 (0.79) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL2277636 | 0.86 | HCRTR1 (1.00) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL7939330 | 0.83 | HCRTR2 (1.00) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL439583 | 0.82 | HCRTR2 (0.70) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL441337 | 0.82 | HCRTR2 (0.69) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL2306422 | 0.81 | HCRTR1 (1.00) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL439302 | 0.80 | HCRTR1 (0.73) | HCRTR1HCRTR2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438041-A1 | PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2012-04-11 | — | — | EP | claimed |
| US-20120065205-A1 | PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2012-03-15 | — | — | US | claimed |
| WO-2010141275-A1 | PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-12-09 | — | — | WO | claimed |
| US-20120065205-A1 | PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2012-03-15 | — | — | US | disclosed |
| US-20120065205-A1 | PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2012-03-15 | — | — | US | disclosed |
| US-20120065085-A1 | Detection of chromosomal abnormalities associated with endometrial cancer | ABBOTT LABORATORIES (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065205-A1 | PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2012-03-15 | — | — | US | disclosed |
| EP-1941060-B1 | PROTEIN DEMETHYLASES COMPRISING A JMJC DOMAIN | UNIV NORTH CAROLINA (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20110217709-A1 | DETECTION OF CHROMSOMAL REGION COPY NUMBER CHANGES TO DIAGNOSE MELANOMA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-08 | — | — | US | disclosed |
| US-7960110-B2 | detecting melanoma. The methods comprises detecting a gain or loss of certain chromosomal regions that undergo copy number changes in melanoma. | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-06-14 | — | — | US | disclosed |
| WO-2011056505-A1 | DETECTION OF CHROMOSOMAL ABNORMALITIES ASSOCIATED WITH PROGNOSIS OF NON SMALL CELL LUNG CANCER | ABBOTT LABORATORIES (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2010141275-A1 | PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065205-A1 | PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY5R | HCRTR1 2/4885HCRTR2 1/4885CYP3A4 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.